Pharmacokinetic and pharmacodynamic similarity evaluation between an insulin glargine biosimilar product and Lantus® in healthy subjects: Pharmacokinetic parameters of both parent insulin glargine and M1 were used as endpoints [PDF]
Frontiers in Pharmacology, 2022 Insulin glargine is a long-acting insulin analog, which plays an important role in the treatment of diabetes mellitus. Biosimilar products of insulin glargine can provide patients with additional safe, high-quality, and potentially cost-effective options
Yiya Wang +7 more
doaj +2 more sources
Evaluation of Early Insulin Glargine Administration in the Treatment of Pediatric Diabetic Ketoacidosis. [PDF]
J Pediatr Pharmacol Ther, 2023 OBJECTIVE In the management of diabetic ketoacidosis (DKA), the standard of care is to administer insulin glargine after ketoacidosis has resolved and the patient is transitioning from intravenous (IV) insulin to subcutaneous insulin; however, there is ...
Welter KJ +4 more
europepmc +2 more sources
Effects of Tirzepatide Versus Insulin Glargine on Cystatin C-Based Kidney Function: A SURPASS-4 Post Hoc Analysis. [PDF]
Diabetes Care, 2023 OBJECTIVE Tirzepatide reduces HbA1c and body weight, and creatinine-based estimated glomerular filtration rate (eGFR) decline. Unlike creatine-derived eGFR (eGFR-creatinine), cystatin C–derived eGFR (eGFR-cystatin C) is unaffected by muscle mass changes.
Heerspink HJL +10 more
europepmc +2 more sources
Insulin analogues dosing and costs - comparing real-life daily doses of insulin detemir and insulin glargine in type 2 diabetes patients [PDF]
BMC Endocrine Disorders, 2012 Background The uncertainties regarding dose similarities between basal long-acting insulin analogues remain. Recent real-world studies indicate dose similarities between insulin detemir and insulin glargine, but further studies are still warranted.
Jakobsen Marie +3 more
doaj +2 more sources
Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial [PDF]
Diabetes Care, 2021 OBJECTIVE Insulin icodec (icodec) is a novel once-weekly basal insulin analog. This trial investigated two approaches for switching to icodec versus once-daily insulin glargine 100 units/mL (IGlar U100) in people with type 2 diabetes receiving daily ...
Harpreet S. Bajaj +10 more
openalex +2 more sources
Electronic medical record cancer incidence over six years comparing new users of glargine with new users of NPH insulin. [PDF]
PLoS ONE, 2014 Recent studies suggested that insulin glargine use could be associated with increased risk of cancer. We compared the incidence of cancer in new users of glargine versus new users of NPH in a longitudinal clinical cohort with diabetes for up to 6 years ...
Soo Lim +8 more
doaj +14 more sources
Efficacy and safety of insulin glargine/lixisenatide fixed‐ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP‐L randomized clinical trial [PDF]
Diabetes, obesity and metabolism, 2020 To assess efficacy and safety of fixed‐ratio (1:1) combination insulin glargine and lixisenatide (iGlarLixi) compared to insulin glargine U100 (iGlar), with metformin, in Japanese patients with type 2 diabetes mellitus (T2DM) inadequately controlled on ...
Hideaki Kaneto +5 more
openalex +2 more sources
Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studies [PDF]
BMC Endocrine Disorders, 2021 Background MYL-1501D is a proposed biosimilar to insulin glargine. The noninferiority of MYL-1501D was demonstrated in patients with type 1 diabetes and type 2 diabetes in 2 phase 3 trials.
Bin Sun +11 more
doaj +2 more sources
Adverse drug events associated with insulin glargine: a real-world pharmacovigilance study based on the FAERS database [PDF]
Frontiers in PharmacologyBackgroundInsulin glargine is a long-acting drug and the first synthetic insulin to mimic human metabolism. The safety of insulin glargine in the real world remains to be further investigated.
Tongtong Wang +7 more
doaj +2 more sources
Insulin glargine 300 U/mL safety data in pregnancy. [PDF]
Diabetes Obes MetabWesterbacka J +4 more
europepmc +3 more sources